Gross Margin

Carlsmed's AI-driven aprevo® platform shows massive surgeon adoption and market growth, signaling a new era of personalized, cost-effective spine care.

With preliminary Q1 revenue of $103.7M, Twist Bioscience beats forecasts, setting a bullish tone ahead of its full earnings report on February 2nd.

The genomics leader posted a 41% revenue surge in 2025 and projects profitability, yet its stock tumbled on what some see as conservative 2026 guidance.

Amidst a strategic push for profitability, CytoSorbents advances its DrugSorb-ATR device, aiming to revolutionize safety in cardiac surgery.

Utz Brands posted strong 2025 profit growth and market share gains, overcoming retail inventory issues caused by economic headwinds like SNAP delays.

Cytek Biosciences reports preliminary 2025 revenue of $201M, beating estimates with a major Q4 growth surge ahead of its key J.P. Morgan presentation.

With booming revenue, a potential blockbuster on the horizon, and key partnerships, Ascendis Pharma lays out a bold roadmap for global dominance.

Beyond a simple time change, Fortrea's upcoming JPM presentation is a critical test for its new CEO and a key moment to define its future in the CRO market.

The automotive giant honored its top vendors, signaling that deep strategic partnerships are crucial to its ongoing operational and financial transformation.

Prescryptive and Ilant Health unveil a direct-to-employer model for obesity drugs, promising transparent pricing and better clinical outcomes for employers.

With 11 straight quarters of growth and a focus on 'Physical AI,' lidar leader Ouster is set to detail its ambitious strategy for institutional investors.

KB Home launches its new Somerset community in Victorville, tapping into high demand with personalized, energy-efficient homes priced from the mid-$400,000s.

Former mayoral candidate Luc Rabouin takes the helm at the $500M Foundation of Greater Montréal, bringing his urban development expertise to shape its future.

ChipMOS reports stunning 20.8% Q4 growth, highlighting a memory chip frenzy fueled by AI and datacenters. Is this the start of a new tech supercycle?

Pandora's 2025 growth slows amid weak consumer sentiment, but a new CEO plans a strategic reset to combat rising costs and boost brand desirability.

Swiss lab automation giant Tecan shows signs of a turnaround with robust H2 2025 orders, betting on AI to navigate a recovering life sciences market.

Record AI mega-deals redefine healthcare innovation, yet a broader market contraction creates a new divide for startups and traditional medical sectors.

The LA Rams and energy firm CRC mark one year of a partnership to offset team emissions, but does this innovative, local-first model truly change the game?

After 30 years, CEO Jim Foster will retire, passing the torch to COO Birgit Girshick in a move that signals continuity and a new era of governance.

The medtech firm's preliminary results show a Q4 revenue uptick but miss yearly estimates, signaling a stabilizing but cautious path forward for 2026.